These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 26459302)
1. Head and neck cancer: metronomic chemotherapy. De Felice F; Musio D; Tombolini V BMC Cancer; 2015 Oct; 15():677. PubMed ID: 26459302 [TBL] [Abstract][Full Text] [Related]
2. Afatinib in squamous cell carcinoma of the head and neck. Specenier P; Vermorken J Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340 [TBL] [Abstract][Full Text] [Related]
4. The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort. Lynggaard CD; Therkildsen MH; Kristensen CA; Specht L Acta Oncol; 2015 Jul; 54(7):1071-5. PubMed ID: 25342535 [No Abstract] [Full Text] [Related]
5. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers. Patil V; Noronha V; Krishna V; Joshi A; Prabhash K Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):388. PubMed ID: 23434353 [No Abstract] [Full Text] [Related]
6. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. Ock CY; Keam B; Kim TM; Han DH; Won TB; Lee SH; Hah JH; Kwon TK; Kim DW; Kim DY; Rhee CS; Wu HG; Sung MW; Heo DS Korean J Intern Med; 2016 May; 31(3):570-8. PubMed ID: 26976150 [TBL] [Abstract][Full Text] [Related]
7. Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Winquist E; Al-Rasheedy I; Nichols AC; Palma DA; Stitt L Cancer Treat Rev; 2014 Oct; 40(9):1073-9. PubMed ID: 25200522 [TBL] [Abstract][Full Text] [Related]
8. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651 [TBL] [Abstract][Full Text] [Related]
9. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Swiecicki PL; Bellile E; Sacco AG; Pearson AT; Taylor JM; Jackson TL; Chepeha DB; Spector ME; Shuman A; Malloy K; Moyer J; McKean E; McLean S; Sukari A; Wolf GT; Eisbruch A; Prince M; Bradford C; Carey TE; Wang S; Nör JE; Worden FP Invest New Drugs; 2016 Aug; 34(4):481-9. PubMed ID: 27225873 [TBL] [Abstract][Full Text] [Related]
11. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308 [TBL] [Abstract][Full Text] [Related]
12. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study. Tiwari S; Goel V; John MC; Patnaik N; Doval DC Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336 [TBL] [Abstract][Full Text] [Related]
14. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates. Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258 [TBL] [Abstract][Full Text] [Related]
15. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study. Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239 [TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131 [TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study. Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F Oncology; 2013; 84(4):251-4. PubMed ID: 23428719 [TBL] [Abstract][Full Text] [Related]
18. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869 [TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567 [TBL] [Abstract][Full Text] [Related]
20. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer. Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]